<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215279</url>
  </required_header>
  <id_info>
    <org_study_id>D3320C00002</org_study_id>
    <nct_id>NCT01215279</nct_id>
  </id_info>
  <brief_title>AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)</brief_title>
  <official_title>A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel Group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the tolerability and safety of AZD2423 in Patients
      with chronic obstructive pulmonary disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Laboratory Variables Other Than Monocytes</measure>
    <time_frame>Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)</time_frame>
    <description>Number of all participants with clinically significant changes in laboratory variables, except monocyte, assessed at all the listed time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Vital Signs</measure>
    <time_frame>Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)</time_frame>
    <description>Number of participants with clinically significant changes in vital signs assessed at all the listed time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in ECG Variables</measure>
    <time_frame>Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)</time_frame>
    <description>Number of participants with clinically significant changes in ECG variables assessed at all the listed time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Physical Examination</measure>
    <time_frame>Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)</time_frame>
    <description>Number of participants with clinically significant changes in physical examination assessed at all the listed time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocytes at Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Monocyte count in peripheral blood at baseline (Pre-dose, Day 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocytes at End of Treatment</measure>
    <time_frame>week 4</time_frame>
    <description>Monocyte count in peripheral blood at end of treatment (4 weeks)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monocytes at Follow-up</measure>
    <time_frame>week 5 (follow-up)</time_frame>
    <description>Monocyte count in peripheral blood at follow-up (Week 5; 1 week after end of treatment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morning FEV1 at Baseline</measure>
    <time_frame>Average of 10 days of pre-treatment measurements (day -10 to -1)</time_frame>
    <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning FEV1 During Last 7 Days of Treatment</measure>
    <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
    <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening FEV1 at Baseline</measure>
    <time_frame>Average of 10 days of pre-treatment measurements (day -10 to -1)</time_frame>
    <description>Measurement conducted by patient in evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening FEV1 During Last 7 Days of Treatment</measure>
    <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
    <description>Measurement conducted by patient in evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Expiratory Flow (PEF) at Baseline</measure>
    <time_frame>Average of 10 days of pre-treatment measurements (day -10 to -1)</time_frame>
    <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning PEF During Last 7 Days of Treatment</measure>
    <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
    <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEF at Baseline</measure>
    <time_frame>Average of 10 days of pre-treatment measurements (day -10 to -1)</time_frame>
    <description>Measurement conducted by patient in evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening PEF During Last 7 Days of Treatment</measure>
    <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
    <description>Measurement conducted by patient in evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Total Score at Baseline</measure>
    <time_frame>Average of 7 days of pre-treatment measurements (day -7 to -1)</time_frame>
    <description>The EXACT Tool is a Patient Reported Outcome (PRO) measure; 14 items evaluated on 5- or 6-point scales; total score ranges from 0 to 100 (higher values indicate more severe exacerbation). Baseline is the mean value over the 7 days prior to randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EXACT Total Score During Last 7 Days of Treatment</measure>
    <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
    <description>The EXACT Tool is a Patient Reported Outcome (PRO) measure; 14 items evaluated on 5- or 6-point scales; total score ranges from 0 to 100 (higher values indicate more severe exacerbation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathlessness, Cough and Sputum Scale (BCSS) (Evening) Total Score at Baseline</measure>
    <time_frame>Average of 10 days of pre-treatment measurements (day -10 to -1)</time_frame>
    <description>The BCSS scale includes one question for each of the symptoms of breathlessness, cough, and sputum. The total BCSS score ranges from 0 to 12; higher scores indicate greater symptom severity. The minimally important difference has been defined as a change in total score of greater than 0.3 units. Baseline is mean of 10 days prior to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BCSS (Evening) Total Score During Last 7 Days of Treatment</measure>
    <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
    <description>The BCSS scale includes one question for each of the symptoms of breathlessness, cough, and sputum. The total BCSS score ranges from 0 to 12; higher scores indicate greater symptom severity. The minimally important difference has been defined as a change in total score of greater than 0.3 units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use During the Last 7 Days of Treatment</measure>
    <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
    <description>Number of inhalations of short acting Î²2 agonist (SABA) or short acting muscarinic antagonist (SAMA) per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire for COPD (SGRQ) Total Score at Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>The SGRQ-C includes 40 questions in 3 domains: Symptoms (distress due to respiratory symptoms, 7 questions), Activity (disturbance of physical activity, 13 questions), Impacts (overall impact on daily life and well-being, 20 questions). Scores are expressed as a percentage. Baseline is Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ Total Score at End of Treatment</measure>
    <time_frame>week 4</time_frame>
    <description>Decrease in score represents improved Quality of Life; increase represents deteriorated Quality of Life. An increase or decrease of 4 or more percent units is judged as the Minimal Clinically Important Difference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCL2 (Chemokine Ligand for CCR2b Receptor) Concentration in Plasma at Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Baseline = Day 1 = Visit 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCL2 Concentration in Plasma at End of Treatment</measure>
    <time_frame>week 4</time_frame>
    <description>End of treatment = 4 weeks = Visit 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Amyloid-A (SAA) Concentration in Plasma at Baseline</measure>
    <time_frame>Day 1</time_frame>
    <description>Baseline = Day 1 = Visit 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAA Concentration in Plasma at End of Treatment</measure>
    <time_frame>week 4</time_frame>
    <description>End of treatment = 4 weeks = Visit 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areaa Under the Curve From 0 to 24 Hours (AUC 0-24), Population Pharmacokinetic Evaluation of AZD2423 at Steady State</measure>
    <time_frame>2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4</time_frame>
    <description>PK-model: 1-compartment population model with first order absorption. AUC was estimated at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, Population Pharmacokinetic Evaluation of AZD2423 at Steady State</measure>
    <time_frame>2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4</time_frame>
    <description>PK-model: 1-compartment population model with first order absorption. Cmaxwas estimated at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Concentration (Tmax) Population Pharmacokinetic Evaluation of AZD2423 at Steady State</measure>
    <time_frame>2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4</time_frame>
    <description>PK-model: 1-compartment population model with first order absorption. tmax was estimated at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at Steady State (Vss/F) Population Pharmacokinetic Evaluation of AZD2423 at Steady State</measure>
    <time_frame>2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4</time_frame>
    <description>PK-model: 1-compartment population model with first order absorption. (Vss/F) was estimated at steady state</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Lung Disease</condition>
  <arm_group>
    <arm_group_label>AZD2423</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD2423 Oral Treatment for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral treatment for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2423</intervention_name>
    <description>100 mg oral treatment once daily for 28 days</description>
    <arm_group_label>AZD2423</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to AZD2423</intervention_name>
    <description>Oral treatment once daily for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of non-child bearing potential. Only women of non-child bearing
             potential are included in the study i.e. women who are permanently or surgically
             sterilised or post menopausal.

          -  Between 40 and 80 years of age at Visit 1

          -  Clinical diagnosis of COPD (GOLD stage 2 or 3)

          -  FEV1/FVC &lt;70% and FEV1 between 30 and 80% of the predicted normal post-bronchodilator
             (GOLD stage 2 or 3)

          -  Current or ex-smokers

        Exclusion Criteria:

          -  Any clinically significant disease or disorder (including history of abnormal immune
             function) which, in the opinion of the Investigator, may either put the subject at
             risk or influence the way the drug works

          -  Any lung disease other than COPD, recent respiratory infections which have not
             resolved fully, active tuberculosis or at risk of reactivation of tuberculosis.

          -  Any abnormal findings in physical examination, blood or urine test results, vital
             signs or ECG at Visit 1 that may put the subject at risk during the study, affect
             their ability to take part or influence the results of the study

          -  Immunisation with a live vaccine within 3 months or other vaccination within 30 days
             before planned start of treatment

          -  Worsening of COPD symptoms within 4 weeks prior to start of study needing
             hospitalisation, oral steroids or antibiotics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Marks-Konczalik, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Russe</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Slovakia</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=207&amp;filename=CSR-D3320C00002.pdf</url>
    <description>CSR-D3320C00002.pdf</description>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>October 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2010</study_first_posted>
  <results_first_submitted>July 15, 2013</results_first_submitted>
  <results_first_submitted_qc>October 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2014</results_first_posted>
  <last_update_submitted>October 17, 2014</last_update_submitted>
  <last_update_submitted_qc>October 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory disease</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 11 centres in 2 countries: 5 in Bulgaria and 6 in Slovakia. The first patient was enrolled on 09 October 2010 and the last patient last visit was on 08 March 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD2423 100 mg</title>
          <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD2423 100 mg</title>
          <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="7.8"/>
                    <measurement group_id="B2" value="60.6" spread="7.2"/>
                    <measurement group_id="B3" value="61.6" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Changes in Laboratory Variables Other Than Monocytes</title>
        <description>Number of all participants with clinically significant changes in laboratory variables, except monocyte, assessed at all the listed time points</description>
        <time_frame>Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Laboratory Variables Other Than Monocytes</title>
          <description>Number of all participants with clinically significant changes in laboratory variables, except monocyte, assessed at all the listed time points</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Changes in Vital Signs</title>
        <description>Number of participants with clinically significant changes in vital signs assessed at all the listed time points</description>
        <time_frame>Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Vital Signs</title>
          <description>Number of participants with clinically significant changes in vital signs assessed at all the listed time points</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Changes in ECG Variables</title>
        <description>Number of participants with clinically significant changes in ECG variables assessed at all the listed time points</description>
        <time_frame>Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in ECG Variables</title>
          <description>Number of participants with clinically significant changes in ECG variables assessed at all the listed time points</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinically Significant Changes in Physical Examination</title>
        <description>Number of participants with clinically significant changes in physical examination assessed at all the listed time points</description>
        <time_frame>Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Physical Examination</title>
          <description>Number of participants with clinically significant changes in physical examination assessed at all the listed time points</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monocytes at Baseline</title>
        <description>Monocyte count in peripheral blood at baseline (Pre-dose, Day 1)</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Monocytes at Baseline</title>
          <description>Monocyte count in peripheral blood at baseline (Pre-dose, Day 1)</description>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.136"/>
                    <measurement group_id="O2" value="0.43" spread="0.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monocytes at End of Treatment</title>
        <description>Monocyte count in peripheral blood at end of treatment (4 weeks)</description>
        <time_frame>week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Monocytes at End of Treatment</title>
          <description>Monocyte count in peripheral blood at end of treatment (4 weeks)</description>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.165"/>
                    <measurement group_id="O2" value="0.55" spread="0.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Monocytes at Follow-up</title>
        <description>Monocyte count in peripheral blood at follow-up (Week 5; 1 week after end of treatment)</description>
        <time_frame>week 5 (follow-up)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Monocytes at Follow-up</title>
          <description>Monocyte count in peripheral blood at follow-up (Week 5; 1 week after end of treatment)</description>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.175"/>
                    <measurement group_id="O2" value="0.52" spread="0.196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning FEV1 at Baseline</title>
        <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
        <time_frame>Average of 10 days of pre-treatment measurements (day -10 to -1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Morning FEV1 at Baseline</title>
          <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.41"/>
                    <measurement group_id="O2" value="1.3" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning FEV1 During Last 7 Days of Treatment</title>
        <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
        <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Morning FEV1 During Last 7 Days of Treatment</title>
          <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.40"/>
                    <measurement group_id="O2" value="1.4" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening FEV1 at Baseline</title>
        <description>Measurement conducted by patient in evening.</description>
        <time_frame>Average of 10 days of pre-treatment measurements (day -10 to -1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Evening FEV1 at Baseline</title>
          <description>Measurement conducted by patient in evening.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.43"/>
                    <measurement group_id="O2" value="1.4" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening FEV1 During Last 7 Days of Treatment</title>
        <description>Measurement conducted by patient in evening.</description>
        <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Evening FEV1 During Last 7 Days of Treatment</title>
          <description>Measurement conducted by patient in evening.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.37"/>
                    <measurement group_id="O2" value="1.4" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Expiratory Flow (PEF) at Baseline</title>
        <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
        <time_frame>Average of 10 days of pre-treatment measurements (day -10 to -1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow (PEF) at Baseline</title>
          <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
          <units>L/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.5" spread="74.73"/>
                    <measurement group_id="O2" value="185.5" spread="74.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning PEF During Last 7 Days of Treatment</title>
        <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
        <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Morning PEF During Last 7 Days of Treatment</title>
          <description>Measurements conducted by patient in morning upon rising, before intake of morning dose of investigational product but after clearing out mucus. Patients was to refrain from taking rescue medication prior to measurement if possible.</description>
          <units>L/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.2" spread="77.24"/>
                    <measurement group_id="O2" value="196.4" spread="83.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEF at Baseline</title>
        <description>Measurement conducted by patient in evening.</description>
        <time_frame>Average of 10 days of pre-treatment measurements (day -10 to -1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEF at Baseline</title>
          <description>Measurement conducted by patient in evening.</description>
          <units>L/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.3" spread="74.27"/>
                    <measurement group_id="O2" value="196.2" spread="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening PEF During Last 7 Days of Treatment</title>
        <description>Measurement conducted by patient in evening.</description>
        <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Evening PEF During Last 7 Days of Treatment</title>
          <description>Measurement conducted by patient in evening.</description>
          <units>L/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.9" spread="82.17"/>
                    <measurement group_id="O2" value="204.7" spread="87.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Total Score at Baseline</title>
        <description>The EXACT Tool is a Patient Reported Outcome (PRO) measure; 14 items evaluated on 5- or 6-point scales; total score ranges from 0 to 100 (higher values indicate more severe exacerbation). Baseline is the mean value over the 7 days prior to randomisation.</description>
        <time_frame>Average of 7 days of pre-treatment measurements (day -7 to -1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbations of Chronic Pulmonary Disease Tool (EXACT) Total Score at Baseline</title>
          <description>The EXACT Tool is a Patient Reported Outcome (PRO) measure; 14 items evaluated on 5- or 6-point scales; total score ranges from 0 to 100 (higher values indicate more severe exacerbation). Baseline is the mean value over the 7 days prior to randomisation.</description>
          <units>Units on scale, 0-100</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" spread="6.99"/>
                    <measurement group_id="O2" value="45.7" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EXACT Total Score During Last 7 Days of Treatment</title>
        <description>The EXACT Tool is a Patient Reported Outcome (PRO) measure; 14 items evaluated on 5- or 6-point scales; total score ranges from 0 to 100 (higher values indicate more severe exacerbation).</description>
        <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>EXACT Total Score During Last 7 Days of Treatment</title>
          <description>The EXACT Tool is a Patient Reported Outcome (PRO) measure; 14 items evaluated on 5- or 6-point scales; total score ranges from 0 to 100 (higher values indicate more severe exacerbation).</description>
          <units>Units on scale, 0-100</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="7.78"/>
                    <measurement group_id="O2" value="44.6" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breathlessness, Cough and Sputum Scale (BCSS) (Evening) Total Score at Baseline</title>
        <description>The BCSS scale includes one question for each of the symptoms of breathlessness, cough, and sputum. The total BCSS score ranges from 0 to 12; higher scores indicate greater symptom severity. The minimally important difference has been defined as a change in total score of greater than 0.3 units. Baseline is mean of 10 days prior to treatment.</description>
        <time_frame>Average of 10 days of pre-treatment measurements (day -10 to -1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Breathlessness, Cough and Sputum Scale (BCSS) (Evening) Total Score at Baseline</title>
          <description>The BCSS scale includes one question for each of the symptoms of breathlessness, cough, and sputum. The total BCSS score ranges from 0 to 12; higher scores indicate greater symptom severity. The minimally important difference has been defined as a change in total score of greater than 0.3 units. Baseline is mean of 10 days prior to treatment.</description>
          <units>Units on scale, 0-12</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.40"/>
                    <measurement group_id="O2" value="5.3" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BCSS (Evening) Total Score During Last 7 Days of Treatment</title>
        <description>The BCSS scale includes one question for each of the symptoms of breathlessness, cough, and sputum. The total BCSS score ranges from 0 to 12; higher scores indicate greater symptom severity. The minimally important difference has been defined as a change in total score of greater than 0.3 units.</description>
        <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>BCSS (Evening) Total Score During Last 7 Days of Treatment</title>
          <description>The BCSS scale includes one question for each of the symptoms of breathlessness, cough, and sputum. The total BCSS score ranges from 0 to 12; higher scores indicate greater symptom severity. The minimally important difference has been defined as a change in total score of greater than 0.3 units.</description>
          <units>Units on scale, 0-12</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="1.68"/>
                    <measurement group_id="O2" value="5.1" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Medication Use During the Last 7 Days of Treatment</title>
        <description>Number of inhalations of short acting Î²2 agonist (SABA) or short acting muscarinic antagonist (SAMA) per day.</description>
        <time_frame>Average of the last 7 days of treatment (week 4)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Medication Use During the Last 7 Days of Treatment</title>
          <description>Number of inhalations of short acting Î²2 agonist (SABA) or short acting muscarinic antagonist (SAMA) per day.</description>
          <units>Inhalations</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.0" lower_limit="1.0" upper_limit="19.3"/>
                    <measurement group_id="O2" value="3.5" spread="1.0" lower_limit="1.0" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St Georgeâs Respiratory Questionnaire for COPD (SGRQ) Total Score at Baseline</title>
        <description>The SGRQ-C includes 40 questions in 3 domains: Symptoms (distress due to respiratory symptoms, 7 questions), Activity (disturbance of physical activity, 13 questions), Impacts (overall impact on daily life and well-being, 20 questions). Scores are expressed as a percentage. Baseline is Day 1.</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>St Georgeâs Respiratory Questionnaire for COPD (SGRQ) Total Score at Baseline</title>
          <description>The SGRQ-C includes 40 questions in 3 domains: Symptoms (distress due to respiratory symptoms, 7 questions), Activity (disturbance of physical activity, 13 questions), Impacts (overall impact on daily life and well-being, 20 questions). Scores are expressed as a percentage. Baseline is Day 1.</description>
          <units>Percent of maximum possible score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" spread="14.96"/>
                    <measurement group_id="O2" value="57.0" spread="19.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SGRQ Total Score at End of Treatment</title>
        <description>Decrease in score represents improved Quality of Life; increase represents deteriorated Quality of Life. An increase or decrease of 4 or more percent units is judged as the Minimal Clinically Important Difference.</description>
        <time_frame>week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>SGRQ Total Score at End of Treatment</title>
          <description>Decrease in score represents improved Quality of Life; increase represents deteriorated Quality of Life. An increase or decrease of 4 or more percent units is judged as the Minimal Clinically Important Difference.</description>
          <units>Percent of maximum possible score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="14.38"/>
                    <measurement group_id="O2" value="52.9" spread="18.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CCL2 (Chemokine Ligand for CCR2b Receptor) Concentration in Plasma at Baseline</title>
        <description>Baseline = Day 1 = Visit 2</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>CCL2 (Chemokine Ligand for CCR2b Receptor) Concentration in Plasma at Baseline</title>
          <description>Baseline = Day 1 = Visit 2</description>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294" lower_limit="83" upper_limit="530"/>
                    <measurement group_id="O2" value="279" lower_limit="111" upper_limit="635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CCL2 Concentration in Plasma at End of Treatment</title>
        <description>End of treatment = 4 weeks = Visit 6</description>
        <time_frame>week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>CCL2 Concentration in Plasma at End of Treatment</title>
          <description>End of treatment = 4 weeks = Visit 6</description>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1286" lower_limit="297" upper_limit="2410"/>
                    <measurement group_id="O2" value="272" lower_limit="97" upper_limit="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Amyloid-A (SAA) Concentration in Plasma at Baseline</title>
        <description>Baseline = Day 1 = Visit 2</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amyloid-A (SAA) Concentration in Plasma at Baseline</title>
          <description>Baseline = Day 1 = Visit 2</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5175" lower_limit="964" upper_limit="54100"/>
                    <measurement group_id="O2" value="4044" lower_limit="376" upper_limit="18600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SAA Concentration in Plasma at End of Treatment</title>
        <description>End of treatment = 4 weeks = Visit 6</description>
        <time_frame>week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>SAA Concentration in Plasma at End of Treatment</title>
          <description>End of treatment = 4 weeks = Visit 6</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6325" lower_limit="671" upper_limit="115000"/>
                    <measurement group_id="O2" value="4032" lower_limit="211" upper_limit="320000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Areaa Under the Curve From 0 to 24 Hours (AUC 0-24), Population Pharmacokinetic Evaluation of AZD2423 at Steady State</title>
        <description>PK-model: 1-compartment population model with first order absorption. AUC was estimated at steady state</description>
        <time_frame>2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Areaa Under the Curve From 0 to 24 Hours (AUC 0-24), Population Pharmacokinetic Evaluation of AZD2423 at Steady State</title>
          <description>PK-model: 1-compartment population model with first order absorption. AUC was estimated at steady state</description>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2780" lower_limit="1370" upper_limit="5410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax, Population Pharmacokinetic Evaluation of AZD2423 at Steady State</title>
        <description>PK-model: 1-compartment population model with first order absorption. Cmaxwas estimated at steady state</description>
        <time_frame>2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax, Population Pharmacokinetic Evaluation of AZD2423 at Steady State</title>
          <description>PK-model: 1-compartment population model with first order absorption. Cmaxwas estimated at steady state</description>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198" lower_limit="90.7" upper_limit="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Concentration (Tmax) Population Pharmacokinetic Evaluation of AZD2423 at Steady State</title>
        <description>PK-model: 1-compartment population model with first order absorption. tmax was estimated at steady state</description>
        <time_frame>2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Concentration (Tmax) Population Pharmacokinetic Evaluation of AZD2423 at Steady State</title>
          <description>PK-model: 1-compartment population model with first order absorption. tmax was estimated at steady state</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" lower_limit="0.82" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution at Steady State (Vss/F) Population Pharmacokinetic Evaluation of AZD2423 at Steady State</title>
        <description>PK-model: 1-compartment population model with first order absorption. (Vss/F) was estimated at steady state</description>
        <time_frame>2 blood samples (pre- and post dose) per visit collected at weeks 1, 2 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD2423 100 mg</title>
            <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution at Steady State (Vss/F) Population Pharmacokinetic Evaluation of AZD2423 at Steady State</title>
          <description>PK-model: 1-compartment population model with first order absorption. (Vss/F) was estimated at steady state</description>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1600" lower_limit="602" upper_limit="3650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD2423 100 mg</title>
          <description>Two 50 mg AZD2423 tablets, once daily for 28 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to match AZD2423 50 mg tablets, once daily for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Institutions or Investigators were permitted to publish or present the study results from their site (or the overall results), providing the article or presentation was submitted to and approved by AstraZeneca beforehand.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anna Malmgren</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

